Policy on the Use of Recombinant DNA
Research involving recombinant DNA conducted at or sponsored by Tulane University, or research conducted by Tulane University faculty members or students, must be conducted in a manner that does not pose a significant risk to the health or safety of laboratory workers, others in the Institution, the public, or the environment. Federal law on use of recombinant DNA mandates the establishment of the IBC, which reviews, approves and oversees projects involving recombinant DNA.
A. All NIH-funded projects involving recombinant DNA techniques must comply with the NIH Guidelines. Non-compliance may result in (i) suspension, limitation, or termination of financial assistance for the noncompliant NIH-funded research project and of NIH funds for recombinant DNA research at the Institution, or (ii) a requirement for prior NIH approval of any or all recombinant DNA projects at the Institution.
B. All non-NIH funded projects involving recombinant DNA techniques conducted at or sponsored by the Institution must comply with the NIH Guidelines. Noncompliance may result in (i) suspension, limitation, or termination of NIH funds for recombinant DNA research at the Institution, or (ii) a requirement for prior NIH approval of any or all recombinant DNA projects at the Institution.
- Tulane University Institutional Biosafety Committee Policy Manual
- Tulane DURC Policy
- Tulane Incident Reporting Policy
- Laboratory Inspection Policy
- Tulane University Policy on Smallpox Vaccine
- IBC Policy on Revising Current or Initiating New Policies
- Requirements for Possession of Permissible Amounts of Select Toxins
